• eFFECTOR and QBI to study anti-viral agent for Covid-19 treatment pharmaceutical-technology
    May 06, 2021
    eFFECTOR Therapeutics and Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), have announced a $5m cooperative agreement for a planned Phase Ib study of zotatifin (eFT226), an anti-viral agent for Covid-19 ...
PharmaSources Customer Service